Nyra Medical, Inc., a medical device business developing a revolutionary transcatheter mitral valve replacement technique, announced today the completion of a $20 million Series A funding round. Vensana Capital and a significant global medical device business led the investment, with Broadview Ventures, Epidarex Capital, and the Georgia Research Alliance Venture Fund also participating. The funds raised will be utilized to help Nyra’s technology through early feasibility clinical trials.
Nyra is developing a transcatheter device (CARLEN) that changes the native mitral valve leaflets using an unique implant to rectify inadequacies that might otherwise result in mitral regurgitation while retaining physiological valve shape.
Nyra Medical is a medical device company with the motto “simplifying transcatheter repair of heart valves…one valve at a time”, developing the CARLEN technology, a transcatheter technology for the treatment of mitral regurgitation. CARLEN preserves the physiological valve geometry while restoring its function, eliminates the risk of stenosis, and offers the benefit of preserving a full range of transcatheter and surgical treatments as future options.
In conjunction with this fresh round of funding, Nyra has appointed Lisa Wipperman Heine as an independent director to its board of directors. Lisa is a seasoned medical technology professional with over 25 years of experience in operational, executive, and board positions.
